Results 21 to 30 of about 1,992 (155)

Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series

Frontiers in Psychiatry, 2022
Cariprazine is a third-generation antipsychotic medication approved for the treatment of schizophrenia and bipolar disorder, with unique pharmacodynamic and pharmacokinetic properties.
Tommaso Vannucchi, Costanza Taddeucci, Lorenzo Tatini   +2 more
doaj   +1 more source

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

European Psychiatry, 2021
Introduction In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes.
Z.B. Dombi, K. Acsai, Á. Barabássy, B. Sebe, I. Laszlovszky, G. Vass, B. Szatmári, M. Patel, W. Earley, G. Németh   +9 more
doaj   +1 more source

Cariprazine in Three Special Different Areas: A Real-World Experience

Neuropsychiatric Disease and Treatment, 2021
Camilla Gesi,1 Silvia Paletta,2 Maria Carlotta Palazzo,1 Bernardo Dell’Osso,1,3 Claudio Mencacci,1 Giancarlo Cerveri2 1Department of Mental Health and Addiction, ASST FBF Sacco, Milan, Italy; 2Department of Mental Health and Addiction, ASST Lodi, Lodi ...
Gesi C, Paletta S, Palazzo M C, Dell'Osso B, Mencacci C, Cerveri G   +5 more
doaj  

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Annals of General Psychiatry, 2020
Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically ...
Andrea Fagiolini, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Schölin, Ingo Bernd Vernaleken   +17 more
doaj   +1 more source

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

Pharmacopsychiatry
Abstract IntroductionCariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e.
Meszár, Viktória, Magyar, Gabriella, Pásztor, Gabriella Mészárosné, Szatmári, Balázs, Péter, Krisztina, Marton, Lívia, Dombi, Zsófia B., Barabássy, Ágota   +7 more
openaire   +2 more sources

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series

Neuropsychiatric Disease and Treatment, 2022
Miguel Bajouco,1– 3 David Mota1,2 1Department of Psychiatry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 3Coimbra Institute for ...
Bajouco M, Mota D
doaj  

Cariprazine as a useful treatment for patients with schizophrenia and antipsychotic-induced extrapyramidal symptoms: a case report and literature review

European Psychiatry, 2022
Introduction The discovery of second-generation antipsychotics represented an authentic breakthrough for the management of psychotic disorders. Nevertheless, they still don’t adequately manage some aspects of these disorders, such as negative symptoms ...
C. Llach, L. Ilzarbe, M. Sagué-Vilavella, N. Arbelo, R. Catalan, F. Gutierrez   +5 more
doaj   +1 more source

Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report

Psychiatry Research Communications, 2022
Past literature highlights that cannabis use increase the risk of developing psychotic disorder. In this case report, the authors describe the employment of cariprazine in the treatment of a young adult male affected by psychosis and co-morbid cannabis ...
Alessandro Gentile, Stefano Marini, Ilaria Matarazzo, Domenico De Berardis, Antonio Ventriglio   +4 more
doaj   +1 more source

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials

European Psychiatry, 2022
Introduction Affective symptoms are a common feature of schizophrenia and define bipolar disorder. Alterations in dopamine neurotransmission and activity at D3-D2 receptors is associated with depressive symptoms providing the rationale for targeting D3 ...
R. Mcintyre, Z. Dombi, Á. Barabássy, G. Németh   +3 more
doaj   +1 more source

Mechanism of action of cariprazine [PDF]

CNS Spectrums, 2016
Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.
openaire   +2 more sources